Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[THE INVESTOR] Celltrion announced on Sept. 9 that CT-P23, its antibody to treat seasonal flu, has obtained a US patent.
This antibody neutralizes Influenza A virus and is effective in diagnosis, prevention and treatment of the virus, the biopharmaceutical company explained.
By Hwang You-mee (glamazon@heraldcorp.com)
This antibody neutralizes Influenza A virus and is effective in diagnosis, prevention and treatment of the virus, the biopharmaceutical company explained.
By Hwang You-mee (glamazon@heraldcorp.com)
